

References

1. Harrison CN, Schaap N, Vannuchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol*. 2017;4:e317-e324.
2. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019. Abstract 7057.
3. Harrison CN, Schapp N, Vannuchi AM, et al. Fedratinib induces spleen responses in patients with myeloproliferative neoplasm-associated intermediate- or high-risk myelofibrosis (MF) previously exposed to ruxolitinib (RUX), regardless of reason for discontinuing RUX. ASH 2019. Abstract 4165.
4. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. ASH 2019. Abstract 668.
5. Harrison CN, Schaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. ASH 2019. Abstract 2207.
6. Mesa RA, Schaap N, Vannuchi AM, et al. Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. ASH 2019. Abstract 704.
7. Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms: beyond JAK inhibitors. *Curr Hematol Malig Rep*. 2019;14:460-468.
8. Mascarenhas J, Komrokji RS, Cavo M, et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: results of a phase 2 randomized study of two dose levels. ASH 2018. Abstract 685.
9. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood*. 2017;130:1125-1131.
10. Kuykendall AT, Shah S, Talati C, et al. Between rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. *Ann Hematol*. 2018;97:435-441.
11. Palandri F, Breccia M, Bonifacio M, et al. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. *Cancer*. 2019 Dec 20. doi: 10.1002/cncr.32664. [Epub ahead of print].
12. Daver N, Dao K-H, Assad A et al. A phase 2 study of the safety and efficacy of INCB050465, a selective PI3K inhibitor, in combination with ruxolitinib in patients with myelofibrosis. ASH 2018. Abstract 353.
13. Bose P, Pemmaraju N, Daver N, et al. Sotatercept (ACE-11) in subjects with MN-associated myelofibrosis and anemia. EHA 2019. Abstract S829.
14. Gerda ST, Vannuchi AM, Passamonti F, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. ASH 2019. Abstract 557.